Comparison of the treatment effect between lenvatinib and atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in pathologically diagnosed metabolic dysfunction–associated steatotic liver disease.

Authors :: Takahashi, Hirokazu
Koshiyama, Yuichi
Mitsumoto, Yasuhide
Kobayashi, Takashi
Hayashi, Hideki
Arai, Taeang
Sawada, Koji
Nonaka, Michihiro
Nakahara, Takashi
Tomita, Kengo
Ito, Takanori
Notsumata, Kazuo
Seko, Yuya
Fujii, Hideki
Aishima, Shinichi
Yoneda, Masato
Toyoda, Hidenori
Sumida, Yoshio
Nakajima, Atsushi
Okanoue, Takeshi
Source :: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p493-493, 151p
Publication Year :: 2024

Full Text Access

Tools